



Figure S1




**Figure S1.** Senescent phenotype of BMVC4-treated cancer cells. MCF7 and HeLa cells were treated with 1 or 10  $\mu\text{M}$  of BMVC4. The cells were counted during the passages and the population doubling was determined. Results were obtained from the average of three independent experiments.

Figure S2



**Figure S2.** BMVC4 induced senescence in *hTERT*-overexpressing U2OS cells. (A) Total cell extracts prepared from U2OS cells harboring vector (Control) or *hTERT* gene under the control of *CMV* (pCMV-*hTERT*) promoter were analyzed for the *hTERT* and *GAPDH* levels using immunoblots. (B) Control or *hTERT*-overexpressing U2OS cells were treated with 10  $\mu$ M of BMVC4. The cells were counted during the passages and the population doubling was determined.

Figure S3



**Figure S3.** BMVC4 induced senescence in *c-myc*-overexpressing VA13 cells. (A) VA13 cells harboring vector (MT2T) or *c-myc* gene under the control of *CMV* (MT2T-Myc) were analyzed for the *c-myc* and *GAPDH* levels using immunoblots. (B) The cells were treated with 10  $\mu$ M of BMVC4, counted during the passages, and the population doubling was determined.